The Rise of Real-World Evidence in Regulatory Strategy, Part 5: RWE in New Cancer Treatments – FDA Watch

Listen on Spotify.

Listen on Apple Podcasts.

In this fifth part of our series in collaboration with Analysis Group, Wayne chats with Dr. Hilary Marston, Principal at Canal Row Advisors; Dr. Donna Rivera, Executive Vice President of Clinical Evidence Modernization at Canal Row Advisors; and Dr. Mei Sheng Duh, Managing Principal and Chief Epidemiologist at Analysis Group. Together, they discuss the growing role of RWE in oncology drug approvals, methodological and statistical considerations for external control arms and RWE-based study designs, addressing bias and confounding in oncology research, improving clinical trial diversity and transportability, evaluating the contribution of components in combination therapies, the impact of breakthrough therapies and evolving standards of care on oncology drug development, the ARPA-H SURPASS initiative and its implications for oncology trials, the role of advanced analytics in modernizing oncology research, and much more.

This episode and the rest of our series do not include the usual Headlines segment.

About Our Guests

Dr. Hilary Marston

Dr. Hilary Marston served for more than a decade as a leader and strategic advisor on national public health policy and is a recognized expert in the clinical and regulatory aspects of medical product and vaccine development. She brings this expertise to her work with biotechnology and drug companies and investors at Canal Row, and prior to this, at Marston Health, LLC, which she founded after her tenure in FDA leadership.

Dr. Marston was FDA’s inaugural Chief Medical Officer, serving as the primary clinical advisor to the Commissioner and leading the office that oversees clinical matters involving multiple FDA product development centers, including financial incentives (e.g., for rare disease product development), targeted grantmaking, and research participant protection policy. She also led the Agency’s response to health crises, including epidemics and medical product shortages.

Dr. Marston previously served as Senior Advisor for Global COVID-19 Response on the White House COVID-19 Response Team, as Director for Medical Biopreparedness and Response at the U.S. National Security Council, and as Policy Advisor for Pandemic Preparedness at the National Institute of Allergy and Infectious Diseases. She also worked at McKinsey & Company and the Bill & Melinda Gates Foundation.

Dr. Marston trained in Internal Medicine and Global Health Equity at Brigham & Women’s Hospital. She completed her M.P.H. at the Harvard School of Public Health.

Dr. Donna Rivera

Dr. Donna Rivera is a pharmacist and pharmacoepidemiologist with expertise in innovative and scientifically rigorous strategies for clinical evidence modernization—real-world data (RWD), real-world evidence (RWE), clinical trial design, artificial intelligence (AI)—from almost 15 years of experience in government, industry, and academia. She is the Executive Vice President of Clinical Evidence Modernization at Canal Row Advisors, focused on the use of RWD, RWE, and AI for drugs, biologics, and devices to support regulatory objectives.

At the FDA, Dr. Rivera was Associate Director for Pharmacoepidemiology in the Oncology Center of Excellence (OCE) and led the Oncology Real-World Evidence Program, a collaborative effort among CDER, CBER, and CDRH to advance the appropriate use of real-world evidence in oncology product development to facilitate patient-centered regulatory decision-making. She directed initiatives to modernize evidence generation through regulatory review of all oncology submissions containing RWE, strategic management of a multimillion dollar regulatory science research portfolio, regulatory policy development, and leadership of partnerships and educational programs. Dr. Rivera contributed to the development of multiple FDA guidances related to RWD and RWE, clinical studies and pragmatic clinical trials, and the regulatory application of AI. She also formed the FDA Oncology AI Program, chairing the Oncology AI Council to guide the use of artificial intelligence applications in regulatory review, research, and policy.

In her prior role at the National Cancer Institute, she led a strategic RWD initiative to facilitate large-scale, longitudinal treatment data linkages with Surveillance, Epidemiology, and End Results (SEER) registry data through collaborative public-private partnerships, as well as other projects to advance data science and pharmacoepidemiology methods and outcomes. She has previous experience in clinical trial design from Stiefel, a GlaxoSmithKline company.

Dr. Rivera is a Fellow of the International Society for Pharmacoepidemiology and serves as an Affiliate Associate Professor at the University of Maryland School of Pharmacy. She has served on federal and international efforts focused on RWE, AI, COVID-19, the Cancer Moonshoot Initiative. She has authored over 90 peer-reviewed publications and presented at scientific conferences nationally and internationally. Dr. Rivera earned her Doctor of Pharmacy and Master of Science in Pharmaceutical Sciences, with a specialization in Pharmacoepidemiology, from the University of Florida College of Pharmacy. She completed an NCI Postdoctoral Fellowship in Pharmacoepidemiology and Pharmacogenomics.

Dr. Mei Sheng Duh

Dr. Mei Sheng Duh, Chief Epidemiologist at Analysis Group, specializes in real-world evidence (RWE) generation for product registration, post-approval safety studies, and health economics and outcomes research (HEOR) of pharmaceuticals, vaccines, and regenerative biotherapeutics. She has led over 50 projects for new molecular entity approvals and product label expansion applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), as well as health technology assessment (HTA) research for submissions to national payers such as the Centers for Medicare and Medicaid Services (CMS) in the US and the UK’s National Institute for Health and Care Excellence (NICE). Her extensive research has appeared in over 350 peer-reviewed publications.

Her work also extends to pharmaceutical liability litigation and securities fraud litigation related to adverse drug events that allegedly led to product recalls, market withdrawals, black box warnings, and FDA limited access programs.

Dr. Duh is an adjunct research associate in the Biostatistics department at the Harvard T.H. Chan School of Public Health. She served as a chairperson of drug safety and epidemiology for the Drug Information Association (DIA) and was an adjunct assistant professor of pharmacoeconomics and pharmacoepidemiology at Massachusetts College of Pharmacy and Allied Health Sciences. Dr. Duh was appointed to an expert panel convened by the Foundation for the National Institutes of Health’s (FNIH’s) Observational Medical Outcomes Partnership (OMOP). She has served as a peer reviewer for several journals, including PharmacoEconomics, the American Journal of Health-System Pharmacy, Chest, Pharmacoepidemiology and Drug Safety, the American Journal of Kidney Diseases, and Therapeutics and Clinical Risk Management. Dr. Duh is also an elected member of the American Society of Hematology (ASH) and a member of the American Society of Clinical Oncology (ASCO), the International Society of Pharmacoepidemiology (ISPE), and the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).

Dr. Duh holds a Doctor of Science in epidemiology from Harvard School of Public Health, and a Master of Public Health from Yale School of Medicine.


Discover more from FDA Watch Podcast

Subscribe to get the latest posts sent to your email.